Case 1: The Diagnosis of Myelofibrosis
Watch
Case 1: Fedratinib Treatment for Myelofibrosis
Case 1: Ruxolitinib Treatment for Myelofibrosis
Case 1: NCCN Guidelines for Treating Myelofibrosis
Case 1: Risk Stratification Models for Myelofibrosis
Case 1: A 68-Year-Old Woman With Primary Myelofibrosis
Myeloproliferative Neoplasms
Experts in myeloproliferative neoplasms review 4 clinical cases and best practices for patients with, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and blast transformation.
Exploring Biomarkers for Immunotherapy Treatment in Lung Cancer
Jamie E. Chaft, MD, discusses biomarkers used to identify patients with lung cancer who would benefit from immunotherapy and the possibility for future biomarkers in this setting.
Liquid Biopsies Become More Common for Gastric and GI Cancers
Joseph Kim, MD, discusses the utility of liquid biopsies in patients with gastric or gastrointestinal cancer at the 2020 GI Cancers Symposium held by the American Society of Clinical Oncology.
Palliative Care Plays Important Role in Advanced Cancers
Kavitha Ramchandran, MD, discusses the role of palliative care for patients with cancer, particularly those with advanced stage disease.
Early Trials in Melanoma Show Better Response After 1 Year
Richard D. Carvajal, MD, discusses 2 therapies in clinical trials registering patients with melanoma.
BTK Inhibitors Improve Responses Relapsed/Refractory Mantle Cell Lymphoma
Andre Goy, MD, discusses the different BTK inhibitors as treatment of patients with relapsed/refractory mantle cell lymphoma.
Investigators Study JAK Inhibitors in Patients With Myelofibrosis
Ruben Mesa, MD, discusses the role of JAK inhibitors, which are currently being investigated in patients with myelofibrosis. He also spoke to what the future of this treatment landscape may be.
Novel Approaches for Stage I HER2+ Breast Cancer
The ExteNET Study & Management of HER2+ Breast Cancer
Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast Cancer
The APHINITY Trial in Early-Stage HER2+ Breast Cancer
Neoadjuvant T-DM1 in Early-Stage HER2+ Breast Cancer
HER2 Heterogeneity and Neoadjuvant Therapy in Breast Cancer
Neoadjuvant Approaches for Early-Stage HER2+ Breast Cancers
HER2 Assessment in Breast Cancer
Update on HER2-Targeted Therapy in Early Breast Cancer
Sara M. Tolaney, MD, MPH, discusses newer approaches to managing early stages of HER2+ breast cancer in both the neoadjuvant and adjuvant spaces.
Treating CLL With BTK Inhibition: Next Steps
Resistance to BTK Targeted Therapy in CLL
BTK Inhibition in CLL: Real-World Data
Combination Therapies With BTK Targeted Therapy in CLL
Long-Term Experience With BTK Inhibitors for CLL
BTK Inhibitors for Elderly Patients With CLL
MRD and 11q Deletions in CLL
Selecting Frontline Therapy for CLL
